Systematic literature review of traits and outcomes reported in randomised controlled trials of asthma with regular dosing of inhaled corticosteroids with short-acting β2-agonist reliever, as-needed ICS/formoterol, or ICS/formoterol maintenance and reliever therapy

Simple item page
dc.contributor.authorRoche N.
dc.contributor.authorYorgancıoğlu A.
dc.contributor.authorCruz A.A.
dc.contributor.authorGarcia G.
dc.contributor.authorLavoie K.L.
dc.contributor.authorAbhijith P.G.
dc.contributor.authorVerma M.
dc.contributor.authorMajumdar A.
dc.contributor.authorChatterjee S.
dc.date.accessioned2024-07-22T08:02:03Z
dc.date.available2024-07-22T08:02:03Z
dc.date.issued2024
dc.description.abstractIntroduction: Asthma treatments based solely on diagnostic label do not benefit patients equally. To identify patient traits that may be associated with improved treatment response to regular inhaled corticosteroid (ICSs) dosing with short-acting β2-agonist reliever or ICS/formoterol-containing therapy, a systematic literature review (SLR) was conducted. Methods: Searches of databases including MEDLINE and Embase identified randomised controlled trials (RCTs) of patients with asthma, aged ≥12 years, published 1998–2022, containing ≥1 regular ICS dosing or ICS/formoterol-containing treatment arm, and reporting patient traits and outcomes of interest. Relevant data was extracted and underwent a feasibility assessment to determine suitability for meta-analysis. Results: The SLR identified 39 RCTs of 72,740 patients and 90 treatment arms, reporting 11 traits and 11 outcomes. Five patient traits (age, body mass index, FEV1, smoking history, asthma control) and five outcomes (exacerbation rate, lung function, asthma control, adherence, time to first exacerbation) were deemed feasible for inclusion in meta-analyses due to sufficient comparable reporting. Subgroups of clinical outcomes stratified by levels of patient traits were reported in 16 RCTs. Conclusion: A systematic review of studies of regular ICS dosing with SABA or ICS/formoterol-containing treatment strategies in asthma identified consistent reporting of five traits and outcomes, allowing exploration of associations with treatment response. Conversely, many other traits and outcomes, although being potentially relevant, were inconsistently reported and limited subgroup reporting meant analyses of treatment response for subgroups of traits was not possible. We recommend more consistent measurement and reporting of clinically relevant patient traits and outcomes in respiratory RCTs. © 2023 GSK
dc.identifier.DOI-ID10.1016/j.rmed.2023.107478
dc.identifier.issn09546111
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11684
dc.language.isoEnglish
dc.publisherW.B. Saunders Ltd
dc.rightsAll Open Access; Hybrid Gold Open Access
dc.subjectAdministration, Inhalation
dc.subjectAdrenal Cortex Hormones
dc.subjectAnti-Asthmatic Agents
dc.subjectAsthma
dc.subjectBronchodilator Agents
dc.subjectBudesonide
dc.subjectDrug Therapy, Combination
dc.subjectFormoterol Fumarate
dc.subjectHumans
dc.subjectRandomized Controlled Trials as Topic
dc.subjectbeta 2 adrenergic receptor stimulating agent
dc.subjectcorticosteroid
dc.subjectformoterol
dc.subjectantiasthmatic agent
dc.subjectbronchodilating agent
dc.subjectbudesonide
dc.subjectcorticosteroid
dc.subjectformoterol fumarate
dc.subjectadolescent
dc.subjectaged
dc.subjectArticle
dc.subjectasthma
dc.subjectbody mass
dc.subjectclinical outcome
dc.subjecthuman
dc.subjectinhalation
dc.subjectlung function
dc.subjectmaintenance therapy
dc.subjectmeta analysis
dc.subjectrandomized controlled trial
dc.subjectsmoking
dc.subjectsystematic review
dc.subjecttherapy
dc.subjecttreatment outcome
dc.subjecttreatment response
dc.subjectasthma
dc.subjectcombination drug therapy
dc.subjectinhalational drug administration
dc.subjectrandomized controlled trial (topic)
dc.titleSystematic literature review of traits and outcomes reported in randomised controlled trials of asthma with regular dosing of inhaled corticosteroids with short-acting β2-agonist reliever, as-needed ICS/formoterol, or ICS/formoterol maintenance and reliever therapy
dc.typeArticle

Files

Collections

Scopus Koleksiyonu